Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Breast Carcinoma In Situ × dexamethasone 21-phosphate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Fatigue 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Breast Carcinoma In Situ 1

Interventions

dexamethasone acetate 1 dexamethasone 21-phosphate 1 auricularum 1 Taxes 1 Ranitidine 1 Paclitaxel 1 Famotidine 1 Diphenhydramine 1 Dexamethasone 1 Cimetidine 1 Calcium Dobesilate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed

130 enrolled 8 charts

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡